PaO – Page 24 – Communicable Diseases Research

Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies

Research

Published on 2020-08-282022-11-01
Journal: Critical Care [Category] COVID-19, MERS,

Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

코로나19 환자의 탯줄유래 중간엽줄기세포치료제: 임상 1상

Article

Published on 2020-08-272022-08-13
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, MERS, 임상, 치료법,

[키워드] aberrant immune response Adverse adverse event adverse events analyzed anti-SARS-CoV-2 antibody assigned both groups Cell Chest computed tomography clinical evaluation Clinical symptoms clinical trial Computed tomography control group coronavirus disease Coronavirus disease 2019 COVID-19 Cytokines death discharged double-blinded Drug development drug treatments enrolled evaluate events facial flushing Fever group Hospitalization hospitalized patient Host-directed therapies Human hypoxia IgG and IgM IgM anti-SARS-CoV-2 antibodies immune responses IMPROVE infusion intravenous intravenous infusion Laboratory parameters Long-term follow-up long-term functional disability long-term treatment Mechanical mechanical ventilation Mesenchymal stem cells MSCs No effective drug non-randomized one patient outcome PaO Patient patients with moderate performed phase Phase 1 pulmonary disease Randomized receiving reduce regimens required Safe serious COVID-19 severe COVID-19 stem cell Stem cell therapy Stem-cell research survivor therapeutic use therapy tissue damage Treatment treatment group Trial Two patient two patients UC-MSC UC-MSCs umbilical Ventilation with COVID-19
[DOI] 10.1038/s41392-020-00286-5 PMC 바로가기 [Article Type] Article

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

Pulmonary Thrombosis or Embolism in a Large Cohort of Hospitalized Patients With Covid-19

Medicine

Published on 2020-08-252022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] Admission anticoagulant (MeSH) Barcelona C-reactive protein collected data consecutive patient correlated COVID-19 CRP CRP level CTPA D-dimer D-dimer level Diagnosis dose Embolism exhibited Factor greater hospital Hospital stay hospitalized patient ICU in-hospital mortality incidence Increased increased risk independent Inpatients laboratory-confirmed low molecular weight mechanical ventilation Older PaO Patient patients without PE peak D-dimer Predictive Prevent pulmonary pulmonary angiography pulmonary embolism (MeSH) pulmonary thrombosis required Thromboinflammation Thromboprophylaxis university hospital was performed
[DOI] 10.3389/fmed.2020.00557 PMC 바로가기 [Article Type] Medicine

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia

코로나19 폐렴 환자에서 토실리주맙과 스테로이드 치료

Research Article

Published on 2020-08-202022-08-13
Journal: PLoS ONE [Category] Biochemistry, COVID-19, MERS, SARS,

[키워드] 95%CI adjusted age analyses anti-inflammatory treatment Comorbidities Comorbidity controls coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pneumonia Cox regression analysis darunavir death defined determine difference early treatment Efficacy Endpoint endpoints Evidence failure group hazard hazard ratio Hospital admission Hydroxychloroquine immune response IMPROVE intravenously Intubated intubation IQR lead male median median age Methylprednisolone non-intubated patient non-intubated patients not intubated outcome overall survival PaO Patient patients with COVID-19 Pneumonia primary endpoint Propensity score Ratio Respiratory failure Result Ritonavir Severe COVID-19 pneumonia single-center study Standard of care steroid steroid treatment Steroids subcutaneously survival Tocilizumab treated patient Treatment treatment with tocilizumab with COVID-19
[DOI] 10.1371/journal.pone.0237831 PMC 바로가기 [Article Type] Research Article

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-08-172022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] 24 hour absolute reduction Administered administration AIFA airway allocation sequence Alpha Anticoagulant anticoagulant therapy Anticoagulant treatment approval Arm Aspergillus assigned assumption average bleeding bleeding event blinded Block randomisation block size BMI Brain Breastfeeding Candida checked childbearing age chronic clinical clinical condition clinically combined use conjunctival contributed corpus Corticosteroid COVID-19 criteria Critical Critically ill cytomegalovirus D-dimer level death defined Delay detect diagnostic discharge dissemination dosage drug dysfunction effective element eligible patient enoxaparin enrolled EudraCT exclusion criteria expected hematemesis hematoma heparin-induced thrombocytopenia Herpe high risk High-dose history hospital hospital discharge Hypothesis ICU ICU free day ICU Patients impairing Inclusion inclusion criteria indicated Infection initial Inpatient intensive care unit interval Intervention Intra-articular intramuscular intravenously invasive Invasive mechanical ventilation investigator Italian limit LMWH low molecular weight low-molecular weight heparin macroscopic major bleeding mechanical ventilation medical intervention Methylprednisolone Mortality mortality rate Myocardial Non-invasive non-invasive ventilation number objective occur ophthalmic organ dysfunction PaO parallel group participant Patient performed Pharyngeal swab Pneumonia positive positive pressure pregnancy test Presence Prophylactic prophylactic dose Prophylaxis protocol random randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly Ratio receive recent recruited recruitment Rectal Bleeding red blood cell reduce reducing Registered required risk of death Safety Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia secondary secure severe disease sick significantly sodium status steroid stratified stroke study drug Study protocol subcutaneously surgical syndrome therapeutic therapeutic doses therapy Treatment treatment group unfractionated heparin Venous Thromboembolism ventilated patient Ventilation website Weighting Withdrawal women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter

Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial

Study Protocol

Published on 2020-08-162022-10-29
Journal: Trials [Category] COVID-19, MERS,

[키워드] acute respiratory distress acute respiratory distress syndrome Acute respiratory failure Analysis ARDS assigned Asymptomatic disease caused coronavirus disease coronavirus disease 19 Corticosteroid Corticosteroids COVID-19 days alive death decrease defined Dexamethasone Efficacy in viral intensive care intention-to-treat principle intravenous intravenous dose Lung protective ventilation mechanical ventilation mechanically ventilated mild respiratory morbidity Mortality multicenter Multisystem organ failure Open-label PaO Patient Primary outcome randomization Randomized Randomly receive reduce SARS-CoV-2 SARS-COV-2 infection secondary outcome severe pneumonia Study protocol syndrome systemic inflammatory response therapy Treatment Trial trial testing Ventilator-free days
[DOI] 10.1186/s13063-020-04643-1 PMC 바로가기 [Article Type] Study Protocol

Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial

중증 또는 치명적인 COVID-19 폐렴의 치료를 위한 Auxora 대 표준 치료: 무작위 대조 시험의 결과

Research

Published on 2020-08-142022-08-13
Journal: Critical Care [Category] MERS, 임상,

[키워드] 95% CI Abstract Administered adverse event Auxora baseline blinded calcium Calcium release-activated calcium Calcium release-activated calcium channel inhibitors channel inhibitor conducted COVID-19 COVID-19 pneumonia CRAC CRAC channel inhibitor CRAC channel inhibitors Critical cytokine demonstrated died dose Efficacy Enrollment FDA Fewer patient Fewer patients Guidance intravenously Invasive mechanical ventilation mechanical ventilation median time nine novel Open-label open-label study design Ordinal Scale outcome PaO Patient patient population patients with COVID-19 placebo-controlled study Pneumonia Proinflammatory cytokine Proinflammatory response proportion Pulmonary endothelium randomization Randomized Randomized controlled trial rate ratio receive receiving Regulatory respiratory respiratory complication Respiratory complications Result resulting risk safety profile Serious Adverse Event Serious Adverse Events Severe COVID-19 pneumonia significantly Standard of care study enrollment the median Time to recovery Tolerability transition Treatment Trial registration Two patient two patients
[DOI] 10.1186/s13054-020-03220-x PMC 바로가기 [Article Type] Research

Acute Kidney Injury in COVID-19 Pneumonia: A Single-Center Experience in Bahrain

Infectious Disease

Published on 2020-08-122022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] Acute kidney injury Admission age AKI Angiotensin receptor blockers angiotensin-converting enzyme inhibitor association Awareness Bahrain chronic clinical collected convalescent plasma coronavirus disease COVID-19 COVID-19 patient COVID-19 pneumonia criteria Critical determine disease disease severity End-stage renal disease excluded experience greater Gulf Hemodialysis hospital Hospitalization Improving In-hospital death in-hospital mortality increased risk information intensive care KDIGO Kidney disease Laboratory less mechanical ventilation medication men Novel coronavirus Observational cohort study outcome PaO Patient patient data patients patients hospitalized patients with AKI Pneumonia reached renal required Respiratory failure Result retrospective Risk factors Seven significantly to define Tocilizumab transplants were used with COVID-19
[DOI] 10.7759/cureus.9693 PMC 바로가기 [Article Type] Infectious Disease

A Predicting Nomogram for Mortality in Patients With COVID-19

COVID-19 환자의 사망률에 대한 예측 노모그램

Public Health

Published on 2020-08-112022-09-12
Journal: Frontiers in Public Health [Category] MERS, 진단,